This year’s Alzheimer’s Association International Conference (AAIC), which took place in Toronto, Canada, on 27-31 July, featured a range of data readouts from companies developing in vitro diagnostics (IVD) for the early diagnosis of Alzheimer’s disease.
A key theme among many presentations was the use of ALZpath’s pTau217 antibody.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The biomarker featured in seven presentations and 30 posters. A presentation from Roche shared new real-world data confirming that its blood-based biomarker, Elecsys pTau217, provided comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology.
³Ô¹ÏºÚÁÏÍø Network sat down with Selena Yu, senior medical analyst at GlobalData, to learn more about the key IVD news from this year’s AAIC and the direction in which Alzheimer’s disease research and development is currently headed.
You can listen to the podcast below:
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
